A new humanized antibody is effective against pathogenic fungi in vitro

Abstract Invasive fungal infections mainly affect patients undergoing transplantation, surgery, neoplastic disease, immunocompromised subjects and premature infants, and cause over 1.5 million deaths every year. The most common fungi isolated in invasive diseases are Candida spp., Cryptococcus spp.,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tomas Di Mambro, Tania Vanzolini, Pierpaolo Bruscolini, Sergio Perez-Gaviro, Emanuele Marra, Giuseppe Roscilli, Marzia Bianchi, Alessandra Fraternale, Giuditta Fiorella Schiavano, Barbara Canonico, Mauro Magnani
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/6f385189ca0d429fa42e42e29b97385e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6f385189ca0d429fa42e42e29b97385e
record_format	dspace
spelling	oai:doaj.org-article:6f385189ca0d429fa42e42e29b97385e2021-12-02T19:16:59ZA new humanized antibody is effective against pathogenic fungi in vitro10.1038/s41598-021-98659-52045-2322https://doaj.org/article/6f385189ca0d429fa42e42e29b97385e2021-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-98659-5https://doaj.org/toc/2045-2322Abstract Invasive fungal infections mainly affect patients undergoing transplantation, surgery, neoplastic disease, immunocompromised subjects and premature infants, and cause over 1.5 million deaths every year. The most common fungi isolated in invasive diseases are Candida spp., Cryptococcus spp., and Aspergillus spp. and even if four classes of antifungals are available (Azoles, Echinocandins, Polyenes and Pyrimidine analogues), the side effects of drugs and fungal acquired and innate resistance represent the major hurdles to be overcome. Monoclonal antibodies are powerful tools currently used as diagnostic and therapeutic agents in different clinical contexts but not yet developed for the treatment of invasive fungal infections. In this paper we report the development of the first humanized monoclonal antibody specific for β-1,3 glucans, a vital component of several pathogenic fungi. H5K1 has been tested on C. auris, one of the most urgent threats and resulted efficient both alone and in combination with Caspofungin and Amphotericin B showing an enhancement effect. Our results support further preclinical and clinical developments for the use of H5K1 in the treatment of patients in need.Tomas Di MambroTania VanzoliniPierpaolo BruscoliniSergio Perez-GaviroEmanuele MarraGiuseppe RoscilliMarzia BianchiAlessandra FraternaleGiuditta Fiorella SchiavanoBarbara CanonicoMauro MagnaniNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-17 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Tomas Di Mambro Tania Vanzolini Pierpaolo Bruscolini Sergio Perez-Gaviro Emanuele Marra Giuseppe Roscilli Marzia Bianchi Alessandra Fraternale Giuditta Fiorella Schiavano Barbara Canonico Mauro Magnani A new humanized antibody is effective against pathogenic fungi in vitro
description	Abstract Invasive fungal infections mainly affect patients undergoing transplantation, surgery, neoplastic disease, immunocompromised subjects and premature infants, and cause over 1.5 million deaths every year. The most common fungi isolated in invasive diseases are Candida spp., Cryptococcus spp., and Aspergillus spp. and even if four classes of antifungals are available (Azoles, Echinocandins, Polyenes and Pyrimidine analogues), the side effects of drugs and fungal acquired and innate resistance represent the major hurdles to be overcome. Monoclonal antibodies are powerful tools currently used as diagnostic and therapeutic agents in different clinical contexts but not yet developed for the treatment of invasive fungal infections. In this paper we report the development of the first humanized monoclonal antibody specific for β-1,3 glucans, a vital component of several pathogenic fungi. H5K1 has been tested on C. auris, one of the most urgent threats and resulted efficient both alone and in combination with Caspofungin and Amphotericin B showing an enhancement effect. Our results support further preclinical and clinical developments for the use of H5K1 in the treatment of patients in need.
format	article
author	Tomas Di Mambro Tania Vanzolini Pierpaolo Bruscolini Sergio Perez-Gaviro Emanuele Marra Giuseppe Roscilli Marzia Bianchi Alessandra Fraternale Giuditta Fiorella Schiavano Barbara Canonico Mauro Magnani
author_facet	Tomas Di Mambro Tania Vanzolini Pierpaolo Bruscolini Sergio Perez-Gaviro Emanuele Marra Giuseppe Roscilli Marzia Bianchi Alessandra Fraternale Giuditta Fiorella Schiavano Barbara Canonico Mauro Magnani
author_sort	Tomas Di Mambro
title	A new humanized antibody is effective against pathogenic fungi in vitro
title_short	A new humanized antibody is effective against pathogenic fungi in vitro
title_full	A new humanized antibody is effective against pathogenic fungi in vitro
title_fullStr	A new humanized antibody is effective against pathogenic fungi in vitro
title_full_unstemmed	A new humanized antibody is effective against pathogenic fungi in vitro
title_sort	new humanized antibody is effective against pathogenic fungi in vitro
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/6f385189ca0d429fa42e42e29b97385e
work_keys_str_mv	AT tomasdimambro anewhumanizedantibodyiseffectiveagainstpathogenicfungiinvitro AT taniavanzolini anewhumanizedantibodyiseffectiveagainstpathogenicfungiinvitro AT pierpaolobruscolini anewhumanizedantibodyiseffectiveagainstpathogenicfungiinvitro AT sergioperezgaviro anewhumanizedantibodyiseffectiveagainstpathogenicfungiinvitro AT emanuelemarra anewhumanizedantibodyiseffectiveagainstpathogenicfungiinvitro AT giusepperoscilli anewhumanizedantibodyiseffectiveagainstpathogenicfungiinvitro AT marziabianchi anewhumanizedantibodyiseffectiveagainstpathogenicfungiinvitro AT alessandrafraternale anewhumanizedantibodyiseffectiveagainstpathogenicfungiinvitro AT giudittafiorellaschiavano anewhumanizedantibodyiseffectiveagainstpathogenicfungiinvitro AT barbaracanonico anewhumanizedantibodyiseffectiveagainstpathogenicfungiinvitro AT mauromagnani anewhumanizedantibodyiseffectiveagainstpathogenicfungiinvitro AT tomasdimambro newhumanizedantibodyiseffectiveagainstpathogenicfungiinvitro AT taniavanzolini newhumanizedantibodyiseffectiveagainstpathogenicfungiinvitro AT pierpaolobruscolini newhumanizedantibodyiseffectiveagainstpathogenicfungiinvitro AT sergioperezgaviro newhumanizedantibodyiseffectiveagainstpathogenicfungiinvitro AT emanuelemarra newhumanizedantibodyiseffectiveagainstpathogenicfungiinvitro AT giusepperoscilli newhumanizedantibodyiseffectiveagainstpathogenicfungiinvitro AT marziabianchi newhumanizedantibodyiseffectiveagainstpathogenicfungiinvitro AT alessandrafraternale newhumanizedantibodyiseffectiveagainstpathogenicfungiinvitro AT giudittafiorellaschiavano newhumanizedantibodyiseffectiveagainstpathogenicfungiinvitro AT barbaracanonico newhumanizedantibodyiseffectiveagainstpathogenicfungiinvitro AT mauromagnani newhumanizedantibodyiseffectiveagainstpathogenicfungiinvitro
_version_	1718376917990637568

A new humanized antibody is effective against pathogenic fungi in vitro

Ejemplares similares